现代糖尿病药物DPP-4i、SGLT-2i和GLP-1RA在白人与亚洲糖尿病患者中的疗效:随机对照试验的系统综述与Meta分析
该系统综述与Meta分析基于64项随机安慰剂对照试验,评估 ethnicity 对DPP-4i、SGLT-2i和GLP-1RA降糖疗效的影响。主要终点为24周时HbA1c相对于安慰剂的绝对变化。结论:SGLT-2i在亚洲人群为主的试验中降糖疗效优于白人为主试验,DPP-4i差异较小,GLP-1RA未见 ethnicity 差异。
要点
- SGLT-2i在亚洲人群为主试验中HbA1c降幅大于白人为主试验。
- DPP-4i的 ethnicity 差异较小,但亚洲人群仍可能更优。
- GLP-1RA降糖疗效未见明显 ethnicity 差异。
核心结论
- SGLT-2i在亚洲人群为主试验中降糖疗效优于白人为主试验,DPP-4i差异较小,GLP-1RA未见 ethnicity 差异。
研究设计与样本
- 系统综述与Meta分析,检索PubMed截至2019年3月的随机安慰剂对照试验。
- 最终纳入64项研究,要求每臂至少50例、人群>70%为亚洲或白人、疗程≥24周。
主要发现
- 主要终点为24周时HbA1c相对于安慰剂的绝对变化,通过计算治疗组与安慰剂组的均差及95%CI评估。
- SGLT-2i在亚洲人群为主试验中的HbA1c降幅大于白人为主试验。
- DPP-4i的 ethnicity 差异较小,但亚洲人群仍可能更优。
- GLP-1RA未观察到 ethnicity 相关的疗效差异。
临床怎么用
- 选择SGLT-2i或DPP-4i时可考虑患者 ethnicity,亚洲人群可能获得更大降糖获益。
- GLP-1RA的疗效不受 ethnicity 显著影响。
局限性
- 基于汇总数据,无法区分东亚与南亚人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The pathophysiology of type 2 diabetes differs markedly by ethnicity. PURPOSE: A systematic review and meta-analysis was conducted to assess the impact of ethnicity on the glucose-lowering efficacy of the newer oral agents, sodium-glucose cotransporter 2 inhibitors (SGLT-2i), glucagon-like peptide 1 receptor agonists (GLP-1RA), and dipeptidyl peptidase 4 inhibitors (DPP-4i), using evidence from randomized clinical trials (RCTs). DATA SOURCES: A literature search was conducted in PubMed of all randomized, placebo-controlled trials of DPP-4i, SGLT-2i, and GLP-1RA. The search strategy was developed based on Medical Subject Headings (MeSH) terms and keywords. STUDY SELECTION: A total of 64 studies that qualified for meta-analysis after full-text review based on predefined inclusion and exclusion criteria-RCTs with at least 50 patients in each arm, >70% of population from Asian or white group, duration ≥24 weeks, and publication up to March 2019-were selected for systematic review and meta-analysis. DATA EXTRACTION: Data extraction was done for aggregated study-level data by two independent researchers. Absolute changes in HbA1c (%) from baseline to 24 weeks between the drug and placebo were considered as the primary end point of the study. DATA SYNTHESIS: Change in HbA1c was evaluated by computing mean differences and 95% CIs between treatment and placebo arms. LIMITATIONS: The study is based on summarized data and could not be separated based on East Asians and South Asians. CONCLUSIONS: The glucose-lowering efficacy of SGLT-2i, and to a lesser extent DPP-4i, was greater in studies of predominantly Asian ethnicity compared with studies of predominantly white ethnicity. There was no difference seen by ethnicity for GLP-1RA.
引用
- Gan S, Dawed AY, Donnelly LA, et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care. 2020. PMID: 33534728. doi:10.2337/dc19-2419
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。